SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-17-148516
Filing Date
2017-04-28
Accepted
2017-04-28 16:47:05
Documents
5
Period of Report
2017-06-13
Effectiveness Date
2017-04-28

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT d385150ddef14a.htm DEF 14A 304656
2 GRAPHIC g385150g01m68.jpg GRAPHIC 31200
3 GRAPHIC g385150g08c20.jpg GRAPHIC 36896
4 GRAPHIC g385150pcpg01.jpg GRAPHIC 173835
5 GRAPHIC g385150pcpg02.jpg GRAPHIC 139690
  Complete submission text file 0001193125-17-148516.txt   831556
Mailing Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306
Business Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36183 | Film No.: 17796446
SIC: 2836 Biological Products, (No Diagnostic Substances)